Willkie Farr & Gallagher advised Cardiovalve in the transaction. Venus Medtech announced its acquisition of Cardiovalve Ltd. (f/k/a Mitraltech Ltd.), a transcatheter mitral and tricuspid valve...
Venus Medtech’s $300 Million Acquisition of Cardiovalve
Marsh McLennan’s $750 Million Senior Notes Offering
Willkie Farr & Gallagher represented the joint book-running managers in the offering. Davis Polk advised Marsh McLennan. Marsh McLennan announced that it priced $400 million aggregate...